immunomodulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
== Awards and honors == Fulbright fellowship for research in pediatric hematology Honorary Doctorate of Science from William Woods College (1972) Honorary service award from the Ohio State University Home Economics Alumni Association Honorary member of the Turkish Society of Hematology Selected as a "Woman of Achievement" by the Group Action Council of Metropolitan St. Louis (1947)
Hofmann rearrangement of 3,4,5-trimethoxyphenylpropionamide. Cyanohydrin reaction between potassium cyanide and 3,4,5-trimethoxybenzaldehyde followed by acetylation and reduction. Henry reaction of 3,4,5-trimethoxybenzaldehyde with nitromethane followed by nitro compound reduction of ω-nitrotrimethoxystyrene. This was the method used by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). Ozonolysis of elemicin followed by reductive amination. Ester reduction of Eudesmic acid's methyl ester followed by halogenation, Kolbe nitrile synthesis, and nitrile reduction. Amide reduction of 3,4,5-trimethoxyphenylacetamide. Reduction of 3,4,5-trimethoxy(2-nitrovinyl)benzene with lithium aluminum hydride. Treatment of tricarbonyl-(η6-1,2,3-trimethoxybenzene) chromium complex with acetonitrile carbanion in THF and iodine, followed by reduction of the nitrile with lithium aluminum hydride.
After a dispute with Yale over his forced retirement and the rights to his invention of electrospray ionization, Fenn moved to Richmond, Virginia to join Virginia Commonwealth University's (VCU) department of chemistry as an analytical chemistry professor. VCU established an engineering department in the late 1990s, and Fenn held a joint professorship between the two departments until his death. Even in his 80s, Fenn enjoyed the opportunity to be in the lab doing research, saying, "I like to mingle and exchange with the young people. It gets me out from underfoot at home."
== Interactions == Even in the form of eye drops, levebunolol may cause hypotension when combined with alpha blockers, calcium channel blockers, tricyclic antidepressants, and other drugs that lower blood pressure. It can also cause severe hypertension (high blood pressure) when combined with sympathomimetic drugs or MAO-A inhibitors, bradycardia (low heart rate) when combined with antiarrhythmics or mefloquine, and hypoglycemia (low blood sugar) when combined with antidiabetic drugs such as insulin.
=== April === 7 April – It was announced that the Leaving Certificate grinds school, the Institute of Education in Dublin with 7,000 pupils, founded by Ray Kearns in 1969, had been sold to a British educational company. 9 April – An emergency was declared and flights into Dublin Airport were suspended briefly when the nose landing gear of a Ryanair flight from Liverpool to Dublin experienced a problem during landing. Four other arriving flights were diverted to Shannon Airport. Visit by Joe Biden
Sources: en.wikipedia.org
Despite its modern (Pharmacopoeia specified) standard structure, storage stability, potency, purity, and unit strength, with its narrow therapeutic index — i.e., difference between its minimum effective dose (MED) and toxic dose (TD) — and, as well, the small difference between its toxic dose and its lethal dose (LD), insulin remains a dangerous, high-alert medication (HAM).
=== Li–Lu === Andreas Libavius (1555–1616), German doctor and alchemist who discovered how prepare hydrochloric acid, ammonium sulfate, etc. Carl Theodore Liebermann (1842–1914), German chemist, known for synthesis of alizarin Willard Libby (1908–1980), American chemist known for development of radiocarbon dating, 1960 Nobel Prize in Chemistry Justus von Liebig (1803–1873), German inventor and pioneer in agricultural and biological chemistry Karl Paul Link (1901–1978), American biochemist, discovered the anticoagulant warfarin John Wilfrid Linnett (1913–1975), British chemist at the Universities of Oxford and Cambridge, known for contributions to theoretical chemistry William Lipscomb (1919–2011), American chemist known for work in nuclear magnetic resonance, theoretical chemistry, boron chemistry, and biochemistry; 1976 Nobel Prize in Chemistry Joseph Lister, 1st Baron Lister (1827–1912), English surgeon known for recognising that putrefaction in wounds is caused by germs Arthur H. Livermore (1915–2009), American science educator and chemist who contributed to the synthesis of penicillin Mikhail Lomonosov (1711–1765), Russian scientist, anticipated the kinetic-molecular theory by 100 years H.
Pulmonary fibrosis involves a gradual replacement of normal lung tissue with fibrotic tissue. Such scar tissue causes an irreversible decrease in oxygen diffusion capacity, and the resulting stiffness or decreased compliance makes pulmonary fibrosis a restrictive lung disease. Pulmonary fibrosis is perpetuated by aberrant wound healing, rather than chronic inflammation. It is the main cause of restrictive lung disease that is intrinsic to the lung parenchyma. In contrast, quadriplegia and kyphosis are examples of causes of restrictive lung disease that do not necessarily involve pulmonary fibrosis. Common genes implicated in fibrosis are Transforming Growth Factor-Beta (TGF-β), Connective Tissue Growth Factor (CTGF), Epidermal Growth Factor Receptor (EGFR), Interleukin-13 (IL-13), Platelet-Derived Growth Factor (PDGF), Wnt/β-catenin signaling pathway, and TNIK. Additionally, chromatin remodeler proteins affect the development of lung fibrosis, as they are crucial for gene expression regulation and their dysregulation can contribute to fibrotic disease progression.
== See also == Cosmetic pharmacology Ergogenic use of anabolic steroids List of doping cases in sport List of drugs used by militaries Natural bodybuilding Neuroenhancement Steroid use in American football
Sources: en.wikipedia.org
==== Metabolic block ==== Nerve function depends on its blood supply. Arresting or inhibiting the blood supply can deprive nerve tissue of oxygen and other essential nutrients to induce a metabolic block, whereby the nerve is unable to function. This block is purely a physiologic problem such that the structure of the nerve is unchanged. If the metabolic block is short in duration, it is completely reversible with no permanent effects. An example of a metabolic block is when a limb "falls asleep" (temporary numbness, paresthesia, and weakness) due to the position of a limb that restricts blood flow. Complete ischema, such as the application of a tourniquet, is followed by hyperexcitability and then loss of nerve function over 60-90 minutes. The ischema is immediately reversible when the block is released, as long as the duration of ischema is not too long, such as 1-2 hours. The first sign of impairment to intraneural blood flow occurs in the epineural blood vessels at about 20-30mm Hg pressure. At pressures of 60-80mmHg there will be complete ischemia. A metabolic block can also be induced by stretching. In animal studies, venous statis was seen at an 8% stretch and at a 15% stretch the blood supply was completely arrested. It's a frequent occurrence that patients receiving a nerve decompression see an immediate improvement in their symptoms, and this is thought to be the restoration of blood flow after a metabolic block as other forms of functional nerve impairment such as neuropraxia and axonmetesis take longer to recover.
== Chemistry == Amino acid sequence: Asp-Cys-Val-Arg-Phe-Trp-Gly-Lys-Cys-Ser-Gln-Thr-Ser-Asp-Cys-Cys-Pro-His-Leu-Ala-Cys-Lys-Ser-Lys-Trp-Pro-Arg-Asn-Ile-Cys-Val-Trp-Asp-Gly-Ser-Val Molecular formula: C177H268N52O50S6 ω-Grammotoxin SIA can be purified from Grammostola rosea venom by reverse phase high performance liquid chromatography.
3 November Nixon addressed the nation on television and radio at 9:30 p.m., Washington time, to announce his plans to end American involvement in the war. Nixon gave his reasons for rejecting immediately removing all troops, framing that option as the "first defeat in our Nation's history" that "would result in a collapse of confidence in American leadership, not only in Asia but throughout the world." Nixon instead reiterated his plan for Vietnamization, "the complete withdrawal of all U.S. combat ground forces and their replacement by South Vietnamese forces on an orderly scheduled timetable" but added that he did not intend to announce details of the timetable. In closing, he described the people who would support his plan for a drawdown as "the great silent majority of my fellow Americans", in contrast to a "vocal minority" of protesters which, if their will prevailed "over reason and the will of the majority", would mean that the United States would have "no future as a free society." A Gallup poll the next day showed that 77% of Americans supported Nixon's Vietnam policy.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.